Search
Filters
Clear All
  • 10
  • 17
  • 138

Phase

  • 4
  • 7
  • 16
  • 2
  • 24
  • 1
  • 106
  • 160
  • 50

Found 165 will-simon trials

A listing of will-simon medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A Phase I First-in-Human Multicenter Randomized Double-Blinded Placebo- Controlled Study of the Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Cancer Survivors with Anthracycline-Induced Cardiomyopathy

M
Michael Murphy, MD
18-79 years
All genders
The primary purpose of this study is to examine the safety and feasibility of delivering allogeneic human mesenchymal stem cells (allo-MSCs) by transendocardial injection to cancer survivors with left ventricular (LV) dysfunction secondary to anthracycline-induced cardiomyopathy (AIC).
Learn More

A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination with Anti-PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors

S
Shadia Jalal, MD
18-100 years
All genders
The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).
Learn More

A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Adult Participants With Selected Advanced Solid Tumors

P
Patrick Loehrer, MD
18-100 years
All genders
In an unbiased CRISPR screen, RIPK1 was identified as a top gene contributing to immunotherapy resistance. In addition, RIPK1 has been reported to drive pancreatic oncogenesis. In murine models, inhibition of RIPK1 kinase activity in the pancreatic tumor microenvironment leads to the replacement of tumor-permissive myeloid infiltrates with innate cells …
Learn More

A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600E Mutations

S
Sandeep Batra, MD
3-25 years
All genders
This phase II trial studies how well veliparib, radiation therapy, and temozolomide work in treating participants with newly diagnosed malignant glioma without H3 K27M or BRAFV600E mutations.
Learn More

Translational Breast Cancer Research Consortium Biospecimen & Outcomes Repository

K
Kathy Miller, MD
18-100 years
Female
The purpose of this study is to develop a repository of clinical data and outcomes, with and without corresponding specimens from individuals who have participated in TBCRC studies.
Learn More

Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL)

U
Utpal Dave, MD
18-100 years
All genders
The purpose of this study is to test the safety and efficacy of combining two drugs, ixazomib and romidepsin. It will also measure the percentage of patients whose tumor completely resolves after receiving ixazomib and romidepsin.
Learn More

Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin

G
Greg Durm, MD
18-100 years
All genders
The purpose of this study is to compare any good and bad effects of usual radiation plus the study treatment, MEDI4736 (durvalumab), to the usual therapy of radiation plus cetuximab in patients with head and neck cancer who cannot take the drug cisplatin.
Learn More

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

S
Shadia Jalal, MD
18-100 years
All genders
This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery.
Learn More

A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor

G
Greg Durm, MD
18-100 years
All genders
This is a single-arm phase II study of continuation immunotherapy with pembrolizumab following initial benefit with a PD-1 or PD-L1 inhibitor.
Learn More

A Phase 1/2 Trial of VX15/2503 in Children Adolescents or Young Adults With Recurrent or Relapsed Solid Tumors

J
James Croop, MD, PhD
1-30 years
All genders
This phase I/II trial studies the side effects and best dose of anti-SEMA4D monoclonal antibody VX15/2503 (VX15/2503) and to see how well it works in treating younger patients with solid tumors that have come back after treatment, or do not respond to treatment.
Learn More
131 - 140 of 165